Back to Search
Start Over
Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel
- Source :
- Radiology
- Publication Year :
- 2021
- Publisher :
- Radiological Society of North America (RSNA), 2021.
-
Abstract
- Vaccination-associated adenopathy is a frequent imaging finding after administration of COVID-19 vaccines that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. To help the medical community address this concern in the absence of studies and evidence-based guidelines, this paper offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States. According to these recommendations, some routine imaging examinations, such as those for screening, should be scheduled before or at least 6 weeks after the final vaccination dose to allow for any reactive adenopathy to resolve. However, there should be no delay of other clinically indicated imaging (e.g., for acute symptoms, short-interval treatment monitoring, urgent treatment planning or complications) due to prior vaccination. The vaccine should be administered on the side contralateral to the primary or suspected cancer, and both doses should be administered in the same arm. Vaccination information (date(s) administered, injection site(s), laterality, and type of vaccine) should be included in every pre-imaging patient questionnaire, and this information should be made readily available to interpreting radiologists. Clear and effective communication between patients, radiologists, referring physician teams and the general public should be considered of the highest priority when managing adenopathy in the setting of COVID-19 vaccination. Summary COVID-19-vaccination–related adenopathy is a frequent imaging finding that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. This special report offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States.
- Subjects :
- medicine.medical_specialty
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
MEDLINE
Lymphadenopathy
Referring Physician
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Multidisciplinary approach
Medical imaging
medicine
Humans
Radiology, Nuclear Medicine and imaging
Radiation treatment planning
Intensive care medicine
Special Report
Vaccines
SARS-CoV-2
business.industry
Vaccination
COVID-19
Cancer
medicine.disease
030220 oncology & carcinogenesis
Radiology
business
Subjects
Details
- ISSN :
- 15271315 and 00338419
- Volume :
- 300
- Database :
- OpenAIRE
- Journal :
- Radiology
- Accession number :
- edsair.doi.dedup.....53253dc43145413774bfd838e08c6c0c